AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference

Rhea-AI Summary

Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced participation by CEO Sue Washer in the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The fireside chat will be available on-demand starting January 11, 2021, at 6:00 AM ET. AGTC focuses on AAV-based gene therapies for rare inherited diseases and is advancing clinical programs for retinal diseases like X-linked retinitis pigmentosa and achromatopsia. The company's expertise in gene therapy technology positions it as a leader in developing treatments for significant unmet clinical needs.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that Sue Washer, President & Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Virtual BioConnect Conference held January 11 – 14, 2021.

The fireside chat will be available to view on-demand beginning Monday, January 11, 2021 at 6:00AM ET through the entirety of the conference and available by visiting http://ir.agtc.com/events-and-presentations.

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Company’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its preclinical programs build on the Company’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR CONTACTS: 
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contact:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com

FAQ

When is the H.C. Wainwright Virtual BioConnect Conference where AGTC CEO will speak?

The H.C. Wainwright Virtual BioConnect Conference is from January 11-14, 2021.

How can I view AGTC's fireside chat at the conference?

The fireside chat will be available on-demand starting January 11, 2021, at 6:00 AM ET.

What diseases is AGTC focusing on with its gene therapies?

AGTC is developing gene therapies for rare inherited diseases, particularly for retinal conditions like X-linked retinitis pigmentosa and achromatopsia.

What is the focus of AGTC's clinical trials?

AGTC's clinical trials focus on improving vision for patients with inherited retinal diseases.

What is AGTC's expertise in gene therapy?

AGTC specializes in developing AAV-based gene therapies and has leading technology for designing and constructing gene therapy elements.